regeneron nasdaq - Search News

Order byBest matchMost fresh

Regeneron To Buy 23andMe For $256M

Regeneron To Buy 23andMe For $256M After Bankruptcy: Here’s What To Know

Me, known for its at-home DNA testing kits, is expected to be obtained by its highest bidder following a bankruptcy auction after reaching a peak valuation of $6 billion.

Blavity on MSN · 4h

· 14h · on MSN

Regeneron Pharmaceuticals to Acquire 23andMe for $256M

· 15h

23andMe, Inc.: Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale

Struggling DNA testing firm 23andMe to be bought for $256m

23andMe says it has entered into an agreement to be acquired by Regeneron Pharmaceuticals for $256m (£192m).

· 13h

· 11h

23andMe (and Your Genetic Data) Sold to Regeneron in Bankruptcy Auction

· 14h

Biotechnology company Regeneron buying 23andMe for $256 million

16hon MSN

Regeneron to buy 23andMe for $256M in court-supervised sale

Regeneron Pharmaceuticals (NASDAQ:REGN) will buy substantially all assets of genetic testing firm 23andMe for a purchase pric

InvestorsHub on MSN17h

Regeneron Shares Climb on Acquisition of 23andMe Assets in Bankruptcy Deal

Regeneron Pharmaceuticals (NASDAQ:REGN) saw its stock rise 2% after announcing it had secured a winning bid to acquire key assets of genetic testing company 23andMe through a bankruptcy auction. The $256 million deal is poised to significantly enhance Regeneron’s capabilities in genetics-driven research and drug development.

Nasdaq4d

Regeneron Pharmaceuticals Celebrates Jury Verdict Against Amgen for Antitrust Violations, Awarding $406.8 Million in Damages

In children aged 8 to 11 years, PRALUENT should be given by a caregiver. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming ...

3don MSN

Regeneron wins over $400M jury award as Amgen found liable in antitrust case

Regeneron (REGN) wins $400M in damages as jury finds Amgen (AMGN) violated antitrust laws by promoting its heart drug Repatha over rival's Praluent. Read more here.

11h

OraSure stock rises following Regeneron’s 23andMe acquisition

The market’s positive reaction to OraSure’s stock today reflects investor confidence in the company’s ongoing relationship with 23andMe under Regeneron’s ownership. The continuation of this relationship is seen as a positive development for OraSure’s revenue prospects.

Nasdaq5d

Beyond The Numbers: 16 Analysts Discuss Regeneron Pharmaceuticals Stock

Throughout the last three months, 16 analysts have evaluated Regeneron Pharmaceuticals (NASDAQ:REGN), offering a diverse set of opinions from bullish to bearish. The following table summarizes ...

Regeneron Continues To Regenerate Its Drug Pipeline, While Keeping Leverage Down

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% rise in 3 years.

Investing.com India15h

Regeneron stock rises on 23andMe assets acquisition

The planned purchase will allow Regeneron to integrate 23andMe’s extensive genetic data into its research efforts, potentially leading to new medical advancements. Regeneron has stated its commitment to maintaining the privacy and security of 23andMe’s customer data,

Nasdaq6d

Citigroup Upgrades Regeneron Pharmaceuticals (LSE:0R2M)

There are 2,406 funds or institutions reporting positions in Regeneron Pharmaceuticals ... author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial ...

Mason Hawkins' Strategic Move: Regeneron Pharmaceuticals Inc. Takes Center Stage

The most significant addition was Regeneron Pharmaceuticals Inc (NASDAQ:REGN), with 114,880 shares, accounting for 3.88% of the portfolio and a total value of $72,860,340 million. The second largest addition to the portfolio was Tripadvisor Inc (NASDAQ:TRIP),